David Festus Moffat

Title: David Festus Moffat: Innovator in Pharmaceutical Chemistry

Introduction

David Festus Moffat is a notable inventor in the field of pharmaceutical chemistry. He has contributed to the development of innovative compounds aimed at treating various diseases. His work focuses on creating effective pharmaceutical compositions that can inhibit specific enzymes related to autoimmune and inflammatory diseases.

Latest Patents

David Moffat holds a significant patent titled "Tert-Butyl N-[2-{4-[6-Amino-5-(2,4-Difluorobenzoyl)-2-Oxopyridin-1(2h)-Yl]-3,5-Difluorophenyl}ethyl]-L-Alaninate Or A Salt, Hydrate Or Solvate Thereof." This invention provides a compound that is useful for inhibiting the activity of a p38 MAP kinase enzyme. The compound and its pharmaceutical composition are designed to treat autoimmune or inflammatory diseases, as well as cell proliferative diseases. Another notable patent is "A,a-Disubstituted Glycine Ester Conjugates Hydrolysable By Carboxylesterases," which involves covalent conjugates that can pass into cells and accumulate active acid hydrolysis products.

Career Highlights

Throughout his career, David Moffat has worked with several prominent companies in the pharmaceutical industry. He has been associated with Chroma Therapeutics Limited and Macrophage Pharma Limited, where he has made significant contributions to drug development and innovation.

Collaborations

David has collaborated with notable professionals in his field, including Alan Hornsby Davidson and Sanjay Ratilal Patel. These collaborations have further enhanced his research and development efforts in pharmaceutical chemistry.

Conclusion

David Festus Moffat is a distinguished inventor whose work in pharmaceutical chemistry has led to the development of innovative compounds for treating various diseases. His contributions continue to impact the field positively.